Nuveen’s Biogen BIIB Stock Holding History

Nuveen’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,200	Closed	-$4K	–	3189
2022 Q3	$4K	Buy	+13,200	New	+$2.8M	﹤0.01%	3212

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen's BIIB Position: Q2 2026 in Review

Nuveen reduced its Biogen (BIIB) stake by 12% in Q2 2026, selling an estimated $7.96M and leaving 317,204 shares worth $68.5M. The position accounts for 0.02% of the portfolio, ranked #544.

Nuveen first reported a position in BIIB in Q2 2013 and has held it in 53 quarters since. The position peaked at $371M in Q4 2019. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Nuveen held 317,204 shares of Biogen worth $68.5M as of Q2 2026.
Nuveen sold 41,634 Biogen shares in Q2 2026, an estimated $7.96M.
Biogen made up 0.02% of Nuveen's portfolio in Q2 2026, its #544 holding.
Nuveen first reported a position in Biogen in Q2 2013 and has held it in 53 quarters since.
Nuveen's Biogen position peaked at $371M in Q4 2019.
1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.